Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research report issued on Monday, Benzinga reports. They presently have a $56.00 price target on the stock. Needham & Company LLC‘s target price points to a potential upside of 474.54% from the stock’s previous close.
Several other research firms have also recently commented on FTH. Lifesci Capital upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, October 27th. William Blair assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. JonesTrading began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price for the company. Finally, Oppenheimer began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.58.
Get Our Latest Stock Analysis on Sensei Biotherapeutics
Sensei Biotherapeutics Trading Down 2.8%
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13). As a group, equities analysts forecast that Sensei Biotherapeutics will post -14.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sensei Biotherapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in FTH. Jump Financial LLC acquired a new stake in shares of Sensei Biotherapeutics during the 3rd quarter valued at about $694,000. AWM Investment Company Inc. grew its stake in shares of Sensei Biotherapeutics by 4.5% in the 3rd quarter. AWM Investment Company Inc. now owns 116,344 shares of the company’s stock valued at $3,460,000 after buying an additional 5,001 shares in the last quarter. State Street Corp acquired a new position in Sensei Biotherapeutics in the third quarter worth approximately $9,262,000. Candriam S.C.A. acquired a new position in Sensei Biotherapeutics in the third quarter worth approximately $9,542,000. Finally, State of Wyoming bought a new position in Sensei Biotherapeutics during the third quarter valued at approximately $25,000. 10.50% of the stock is owned by hedge funds and other institutional investors.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
